SNORD71: A RNA-Binding Protein with Potential as A Drug Target

Target Name: SNORD71

NCBI ID: G692111

SNORD71

SNORD71: A RNA-Binding Protein with Potential as A Drug Target

SNORD71 (HBII-239) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-binding proteins known as HNPs, which include several different subfamilies, including the SNORFs, SNORDs, and HNPRs. SNORD71 is characterized by its unique structure, which consists of a nucleotide-binding oligomerization domain (NBD) and a protein-coding domain.

The NBD is a small protein that is composed of a nucleotide-binding domain and a carboxylic acid-containing tail. The NBD is responsible for binding to specific nucleotides in the target RNA, and it is a key structural element that allows SNORD71 to interact with other proteins. The carboxylic acid-containing tail of the NBD is important for its stability and for interacting with the target RNA.

SNORD71 is expressed in many different tissues of the body, including the brain, heart, and kidneys. In the brain, SNORD71 is found in the basal ganglia, which is responsible for the coordination of motor movement and the regulation of behavioral state. In the heart, SNORD71 is found in the cardiac muscle cells, where it is involved in the regulation of contractions and the maintenance of heart rate. In the kidneys, SNORD71 is found in the podocytes, which are responsible for filtering blood from the kidneys.

SNORD71 has also been shown to be involved in several different biological processes in the body. For example, it has been shown to be involved in the regulation of gene expression, which is the process by which the instructions in a DNA molecule are used to build a protein. Specifically, SNORD71 has been shown to interact with the protein p21, which is a transcription factor that is involved in the regulation of gene expression.

SNORD71 has also been shown to be involved in the regulation of cellular signaling pathways. For example, it has been shown to be involved in the regulation of the protein kinase Akt, which is a key regulator of cell growth and survival. Specifically, SNORD71 has has been shown to interact with the protein p300, which is a phosphorylated protein that is involved in the regulation of Akt activity.

SNORD71 has also been shown to be involved in the regulation of inflammation. For example, it has been shown to be involved in the regulation of the cytokine interferon-gamma (IFN-纬), which is a pro-inflammatory cytokine that is involved in the regulation of immune responses and inflammation. Specifically, SNORD71 has been shown to interact with the protein NF-kappa-B, which is a transcription factor that is involved in the regulation of inflammation.

SNORD71 is also a potential drug target. Its unique structure and the involvement in several different biological processes make it an attractive target for drug development. Additionally, SNORD71 has been shown to be involved in several different diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, it is important to further study the function and role of SNORD71 in these diseases in order to develop new treatments.

In conclusion, SNORD71 is a protein that is expressed in various tissues of the body and is involved in several different biological processes. Its unique structure and the involvement in the regulation of several different processes make it an attractive target for drug development. Further research is needed to further understand the function and role of SNORD71 in these diseases and to develop new treatments.

Protein Name: Small Nucleolar RNA, C/D Box 71

The "SNORD71 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD71 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets